Filing Flows › Companies › Agios Pharmaceuticals › Timeline
Agios Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−27.1% to $29.41
Agios Pharmaceuticals (AGIO) stock fell 27% over the last 252 sessions, to $29.41. On the way it reported 4 quarters, its insiders filed 1 open-market trade and 4 Form 144 notices of planned sales, and the company filed 1 material 8-K. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: beat the EPS estimate by 11.4% | −10.4% (−5.9% vs SPY) | — | — |
| Oct 26, 2026 | Form 144 | Form 144: Sarah Gheuens plans to sell $296K | −0.4% (−1.1% vs SPY) | −19.2% (−18.6% vs SPY) | — |
| Oct 21, 2026 | Form 144 | Form 144: Sarah Gheuens plans to sell $56K | +1.5% (+0.9% vs SPY) | +3.7% (+3.6% vs SPY) | — |
| Aug 4, 2026 | Form 144 | Form 144: Sarah Gheuens plans to sell $914K | +3.4% (+1.6% vs SPY) | +6.5% (+4.5% vs SPY) | +11.3% (+10.8% vs SPY) |
| Jul 30, 2026 | Earnings | Earnings: missed the EPS estimate by -1.5% | −6.7% (−8.3% vs SPY) | −9.9% (−15.2% vs SPY) | −2.1% (−7.7% vs SPY) |
| Jul 1, 2026 | Form 144 | Form 144: Sarah Gheuens plans to sell $151K | −0.1% (+0.1% vs SPY) | +14.2% (+14.4% vs SPY) | −12.5% (−11.8% vs SPY) |
| Jun 18, 2026 | 8-K | Directors and officers: departures, appointments, pay | +2.7% (+3.0% vs SPY) | +10.4% (+12.8% vs SPY) | +8.9% (+8.7% vs SPY) |
| Apr 29, 2026 | Earnings | Earnings: beat the EPS estimate by 5.7% | +12.3% (+12.3% vs SPY) | +9.3% (+7.6% vs SPY) | +20.4% (+14.6% vs SPY) |
| Mar 3, 2026 | Insider sale | Washburn Theodore James Jr. sold $152K | −2.5% (−1.6% vs SPY) | −2.3% (−1.1% vs SPY) | +14.7% (+19.8% vs SPY) |
| Feb 12, 2026 | Earnings | Earnings: beat the EPS estimate by 4.9% | +1.3% (+2.9% vs SPY) | +3.1% (+4.2% vs SPY) | +0.5% (+4.9% vs SPY) |
Insiders’ record here
In the year on the chart, Agios Pharmaceuticals' insiders reported 0 open-market buys ($0) and 1 sale ($152K). Of the 1 old enough to score, 1 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −18.6%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Agios Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.